Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

被引:32
|
作者
Gaglio, Paul [1 ,2 ]
Marfo, Kwaku [1 ,2 ]
Chiodo, Joseph, III [3 ]
机构
[1] Montefiore Med Ctr, Div Hepatol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Otsuka Amer Pharmaceut Inc, Med Sci Liaison, Rockville, MD USA
关键词
Arginine vasopressin; MELD score; Portal hypertension; Vasopressin receptor antagonists; SERUM SODIUM CONCENTRATION; V-2 RECEPTOR ANTAGONIST; PRETRANSPLANT HYPONATREMIA; HEPATIC-ENCEPHALOPATHY; RISK-FACTORS; ASCITES; MULTICENTER; SATAVAPTAN; CONIVAPTAN; MANAGEMENT;
D O I
10.1007/s10620-012-2276-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increased mortality in cirrhotic patients, those with end-stage liver disease (ESLD) on transplant waiting lists, and, in some studies, posttransplantation patients. Clinical evidence suggests that adding serum sodium to model for ESLD (MELD) scoring identifies patients in greatest need of liver transplantation by improving waiting list mortality prediction. Hyponatremia is also associated with numerous complications in liver disease patients, including severe ascites, hepatic encephalopathy, infectious complications, renal impairment, increased severity of liver disease in cirrhosis, and increased hospital stay and neurologic/infectious complications posttransplant. Vasopressin receptor antagonists, which act to increase free water excretion (aquaresis) and thereby increase serum sodium concentration, have been evaluated in patients with hypervolemic hyponatremia (including cirrhosis and heart failure) and euvolemic hyponatremia (SIADH). Tolvaptan, a selective vasopressin V-2-receptor antagonist, is the only oral agent in this class approved for raising sodium levels in hypervolemic and euvolemic hyponatremia. The SALT trials showed that tolvaptan treatment rapidly and effectively resolved hyponatremia in these settings, including cirrhosis, and it has been shown that this agent can be safely and effectively used in long-term treatment. Fluid restriction should be avoided during the first 24 h of treatment to prevent overly rapid correction of hyponatremia, and tolvaptan should not be used in patients who cannot sense/respond to thirst, anuric patients, hypovolemic patients, and/or those requiring urgent intervention to raise serum sodium acutely.
引用
收藏
页码:2774 / 2785
页数:12
相关论文
共 50 条
  • [1] Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan
    Paul Gaglio
    Kwaku Marfo
    Joseph Chiodo
    Digestive Diseases and Sciences, 2012, 57 : 2774 - 2785
  • [2] Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease—Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan
    A. Abhyankar
    S. C. Robson
    E. B. Tapper
    A. Bonder
    Digestive Diseases and Sciences, 2013, 58 : 889 - 890
  • [3] Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease-Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan
    Abhyankar, A.
    Robson, S. C.
    Tapper, E. B.
    Bonder, A.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (03) : 889 - 890
  • [4] Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
    Schrier, Robert W.
    Gross, Peter
    Gheorghiade, Mihai
    Berl, Tomas
    Verbalis, Joseph G.
    Czerwiec, Frank S.
    Orlandi, Cesare
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20): : 2099 - 2112
  • [5] Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan
    Friedman, Bruce
    Cirulli, Joshua
    JOURNAL OF CRITICAL CARE, 2013, 28 (02) : 219.e1 - 219.e12
  • [6] A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study
    Kiritani, Sho
    Kaneko, Junichi
    Miyata, Yoichi
    Matsumura, Masaru
    Akamatsu, Nobuhisa
    Ishizawa, Takeaki
    Arita, Junichi
    Tamura, Sumihito
    Kokudo, Norihiro
    Hasegawa, Kiyoshi
    BIOSCIENCE TRENDS, 2019, 13 (02) : 189 - 196
  • [7] Hyponatremia correction with an oral vasopressin V2-receptor antagonist
    Al-Awqati, Qais
    KIDNEY INTERNATIONAL, 2007, 71 (04) : 288 - 288
  • [8] Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis
    Cardenas, Andres
    Gines, Pere
    Marotta, Paul
    Czerwiec, Frank
    Oyuang, John
    Guevara, Monica
    Afdhal, Nezam H.
    JOURNAL OF HEPATOLOGY, 2012, 56 (03) : 571 - 578
  • [9] Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia
    Habib, Shahid
    Boyer, Thomas D.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (03): : 189 - 197
  • [10] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187